The congress of the European Society of Medical Oncology (ESMO) that recently took place virtually was marked by highlights in many different cancer types. New therapeutic options especially in metastatic breast cancer will hopefully bring a longer life to thousands of patients all over the world. These include new antibody-drug conjugates (ADCs) and checkpoint inhibitors as well as cyclin-dependent kinase (CDK)4/6 inhibitors prolonging overall survival. In Her2-positive advanced breast cancer trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine showed a superior benefit in progression-free survival (PFS) in patients who received at least one prior therapy line in the metastatic setting. In the first-line treatment of metastatic triple-negative breast cancer, an overall survival (OS) benefit of pembrolizumab plus chemotherapy versus chemotherapy alone was confirmed for patients with a combined positive score (CPS) ≥ 10. Final results of MONALESSA‑2 demonstrated a great OS benefit for the cyclin dependent kinase (CDK)4/6 inhibitor ribociclib plus endocrine therapy as first-line treatment of patients with hormone receptor (HR)-positive, Her2-negative breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073810 | PMC |
| http://dx.doi.org/10.1007/s12254-022-00810-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Online Interactive Decision Tools on Women's Decision-Making Regarding Breast Cancer Screening: Systematic Review and Meta-Analysis.
J Med Internet Res
January 2025
Cancer Screening, American Cancer Society, Atlanta, GA, United States.
Background: The online nature of decision aids (DAs) and related e-tools supporting women's decision-making regarding breast cancer screening (BCS) through mammography may facilitate broader access, making them a valuable addition to BCS programs.
Objective: This systematic review and meta-analysis aims to evaluate the scientific evidence on the impacts of these e-tools and to provide a comprehensive assessment of the factors associated with their increased utility and efficacy.
Methods: We followed the 2020 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and conducted a search of MEDLINE, PsycINFO, Embase, CINAHL, and Web of Science databases from August 2010 to April 2023.
Social health determinants associated with mammography performance according to the 2013 and 2019 National Health Survey.
Cien Saude Colet
January 2025
Universidade Federal do Ceará. R. Alexandre Baraúna 1115, Rodolfo Teófilo. 60430-160 Fortaleza CE Brasil.
Mammography is one of the main methods available for breast cancer screening in Brazil. However, differences in timely access and performance of the exam can be highlighted based on social determinants of health, considered relevant due to their influence on the health situation of a population. Thus, the present study aimed to identify the social determinants of health associated with access to and performance of mammography in Brazilian women.
View Article and Find Full Text PDFMaterial deprivation, racial inequalities and mortality from female breast, prostate, and cervical neoplasm in the Brazilian adult population: an ecological study.
Cien Saude Colet
January 2025
Instituto René Rachou, Fundação Oswaldo Cruz (Fiocruz Minas). Av. Augusto de Lima 1715, Barro Preto. 30190-002 Belo Horizonte MG Brasil.
This article aims to identify the relationship between material deprivation and mortality from breast, cervical, and prostate neoplasms in the Brazilian adult population and the relationship between ethnicity/skin color and material deprivation. This cross-sectional ecological study calculated the mean mortality rate per 100,000 inhabitants, and deaths were standardized by age and gender and redistributed per to ill-defined causes, stratified by age group and ethnicity/skin color. We applied the Negative Binomial model, containing the interaction between ethnicity/skin color and the Brazilian Deprivation Index (IBP).
View Article and Find Full Text PDFClassification-based pathway analysis using GPNet with novel P-value computation.
Brief Bioinform
November 2024
Center for Artificial Intelligence Research, Wake Forest University School of Medicine, Winston-Salem, NC 27101, United States.
Pathway analysis plays a critical role in bioinformatics, enabling researchers to identify biological pathways associated with various conditions by analyzing gene expression data. However, the rise of large, multi-center datasets has highlighted limitations in traditional methods like Over-Representation Analysis (ORA) and Functional Class Scoring (FCS), which struggle with low signal-to-noise ratios (SNR) and large sample sizes. To tackle these challenges, we use a deep learning-based classification method, Gene PointNet, and a novel $P$-value computation approach leveraging the confusion matrix to address pathway analysis tasks.
View Article and Find Full Text PDFReplication-Poison Treatment in BRCA1-Deficient Breast Cancer Causes MRE11 Over-Resection that Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe.
Cancer Res
January 2025
INSERM U1194, Montpellier Cedex 05, Occitanie, France.
BRCA1 deficiency is observed in approximately 25% of triple-negative breast cancer (TNBC). BRCA1, a key player of homologous recombination (HR) repair, is also involved in stalled DNA replication fork protection and repair. Here, we investigated the sensitivity of BRCA1-deficient TNBC models to the frequently used replication chain terminator gemcitabine, which does not directly induce DNA breaks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!